Key points from article :
In an exciting development for brain cancer treatment, Paul Read, a 62-year-old patient with glioblastoma, has experienced a 50% reduction in his tumor size after participating in a trial of a new radioactive therapy at University College London Hospitals NHS Foundation Trust (UCLH). The innovative approach involves injecting a radioactive drug, ATT001, directly into the tumour using an Ommaya reservoir, allowing for targeted destruction of cancer cells while preserving surrounding healthy tissue.
Dr. Paul Mulholland, the trial's chief investigator, described the results as "remarkable," particularly given the aggressive nature of glioblastoma, which typically has a grim prognosis. Read had previously undergone surgery, radiotherapy, and chemotherapy before being enrolled in the trial, where he expressed optimism about the potential benefits of the treatment—not just for himself but for future patients as well. With this being the first human study, researchers hope to refine the method and expand its application in future trials.
